[{"id":"7a55dd21-17fa-4758-9f8c-76ac780a7858","acronym":"","url":"https://clinicaltrials.gov/study/NCT04750928","created_at":"2021-02-11T12:52:56.866Z","updated_at":"2025-02-25T12:27:56.800Z","phase":"Phase 1/2","brief_title":"Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas","source_id_and_acronym":"NCT04750928","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 11/29/2021","start_date":" 11/29/2021","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-02-24"},{"id":"15fc70e8-4f11-459e-b3ee-4470ced3ad18","acronym":"EPIK-B5","url":"https://clinicaltrials.gov/study/NCT05038735","created_at":"2021-09-09T13:53:04.798Z","updated_at":"2025-02-25T14:16:18.971Z","phase":"Phase 3","brief_title":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.","source_id_and_acronym":"NCT05038735 - EPIK-B5","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER • PIK3CA","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • fulvestrant"],"overall_status":"Recruiting","enrollment":" Enrollment 234","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/29/2027","study_completion_date":" 12/29/2027","last_update_posted":"2025-02-18"},{"id":"dc4d04a6-0615-4ba1-8e7e-f73bd8437cb0","acronym":"CAAA603B12101","url":"https://clinicaltrials.gov/study/NCT05870579","created_at":"2023-05-23T16:06:09.074Z","updated_at":"2025-02-25T14:42:04.037Z","phase":"Phase 1","brief_title":"[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer","source_id_and_acronym":"NCT05870579 - CAAA603B12101","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • fulvestrant • goserelin acetate • AAA603"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 11/13/2023","start_date":" 11/13/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 01/26/2032","study_completion_date":" 01/26/2032","last_update_posted":"2025-02-14"},{"id":"c5c6214b-5158-4684-8fe9-74226f7c6e70","acronym":"","url":"https://clinicaltrials.gov/study/NCT03439735","created_at":"2021-01-18T16:57:58.769Z","updated_at":"2025-02-25T15:10:45.531Z","phase":"Phase 2","brief_title":"Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC","source_id_and_acronym":"NCT03439735","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/20/2018","start_date":" 07/20/2018","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-13"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"96089508-6422-493f-82c5-12ed65ed1d61","acronym":"ELCIN","url":"https://clinicaltrials.gov/study/NCT05596409","created_at":"2022-10-27T15:58:31.639Z","updated_at":"2025-02-25T16:33:10.407Z","phase":"Phase 2","brief_title":"ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study","source_id_and_acronym":"NCT05596409 - ELCIN","lead_sponsor":"Stemline Therapeutics, Inc.","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orserdu (elacestrant)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/19/2023","start_date":" 05/19/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-02-07"},{"id":"d6077c21-17bb-4f1e-9fd6-5e8d472b76ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03854903","created_at":"2021-01-18T19:01:32.210Z","updated_at":"2025-02-25T16:37:21.932Z","phase":"Phase 1","brief_title":"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor","source_id_and_acronym":"NCT03854903","lead_sponsor":"Georgetown University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 01/09/2025","study_completion_date":" 01/09/2025","last_update_posted":"2025-02-06"},{"id":"0d7fca80-0420-4ead-a6c7-20e34e32d1a2","acronym":"pionERA Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06065748","created_at":"2023-10-04T16:11:25.824Z","updated_at":"2025-02-25T16:47:04.424Z","phase":"Phase 3","brief_title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","source_id_and_acronym":"NCT06065748 - pionERA Breast Cancer","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER • CDK4","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation","tags":["HER-2 • ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 1050","initiation":"Initiation: 12/11/2023","start_date":" 12/11/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-02-05"},{"id":"5b3bbfcb-81b9-4094-b5ab-f48bff41c08a","acronym":"NCI-2022-04099","url":"https://clinicaltrials.gov/study/NCT05372640","created_at":"2022-05-13T12:54:24.439Z","updated_at":"2025-02-25T16:46:03.280Z","phase":"Phase 1","brief_title":"Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors","source_id_and_acronym":"NCT05372640 - NCI-2022-04099","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NUTM1","pipe":"","alterations":" ","tags":["NUTM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-05"},{"id":"f65dd733-9008-4681-bf13-626c30073cdc","acronym":"SAFIR 03","url":"https://clinicaltrials.gov/study/NCT05625087","created_at":"2022-11-22T15:59:03.927Z","updated_at":"2025-02-25T15:54:42.995Z","phase":"Phase 2","brief_title":"Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib","source_id_and_acronym":"NCT05625087 - SAFIR 03","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" HR positive • HER-2 overexpression • HER-2 negative • PIK3CA mutation • HER-2 overexpression + HR positive","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 overexpression • HER-2 negative • PIK3CA mutation • HER-2 overexpression + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • Kisqali (ribociclib) • fulvestrant • triptorelin"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 10/19/2023","start_date":" 10/19/2023","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 06/01/2030","study_completion_date":" 06/01/2030","last_update_posted":"2025-01-30"},{"id":"f72d1e94-e1dc-4d45-b89e-32b26275924e","acronym":"INAVO121","url":"https://clinicaltrials.gov/study/NCT05646862","created_at":"2022-12-12T15:00:20.879Z","updated_at":"2025-02-25T17:38:18.344Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy","source_id_and_acronym":"NCT05646862 - INAVO121","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PIK3CA • CDK4","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation","tags":["HER-2 • PIK3CA • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • fulvestrant • Itovebi (inavolisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 06/07/2023","start_date":" 06/07/2023","primary_txt":" Primary completion: 03/30/2029","primary_completion_date":" 03/30/2029","study_txt":" Completion: 03/30/2029","study_completion_date":" 03/30/2029","last_update_posted":"2025-01-29"},{"id":"fe616f09-6291-4f55-8056-8b008452edb9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06757634","created_at":"2025-02-25T20:04:40.854Z","updated_at":"2025-02-25T20:04:40.854Z","phase":"Phase 3","brief_title":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)","source_id_and_acronym":"NCT06757634","lead_sponsor":"Celcuity Inc","biomarkers":" PIK3CA","pipe":"","alterations":" ","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Kisqali (ribociclib) • fulvestrant • gedatolisib (PF-05212384)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 674","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-01-07"},{"id":"2a0a65eb-7070-4f82-aa45-cd643230d258","acronym":"MAINTAIN","url":"https://clinicaltrials.gov/study/NCT02632045","created_at":"2021-01-18T12:47:59.106Z","updated_at":"2025-02-25T15:42:47.979Z","phase":"Phase 2","brief_title":"Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer","source_id_and_acronym":"NCT02632045 - MAINTAIN","lead_sponsor":"Melissa K Accordino","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • fulvestrant"],"overall_status":"Completed","enrollment":" Enrollment 169","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 01/04/2022","primary_completion_date":" 01/04/2022","study_txt":" Completion: 01/04/2022","study_completion_date":" 01/04/2022","last_update_posted":"2024-12-06"},{"id":"e0eae0c1-fbd3-4860-8074-47f0db5f46f5","acronym":"CHARGE","url":"https://clinicaltrials.gov/study/NCT04315233","created_at":"2021-01-18T20:54:52.326Z","updated_at":"2025-02-25T15:43:56.139Z","phase":"Phase 1","brief_title":"Ribociclib\u0026Belinostat In Patients w Metastatic Triple Neg Breast Cancer \u0026 Recurrent Ovarian Cancer w Response Prediction By Genomics","source_id_and_acronym":"NCT04315233 - CHARGE","lead_sponsor":"University of Utah","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • Beleodaq (belinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 05/03/2021","start_date":" 05/03/2021","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-10-30"},{"id":"797f38fb-e32f-4728-86c9-79fdb962bf09","acronym":"OBU-BC-II-164","url":"https://clinicaltrials.gov/study/NCT06650748","created_at":"2025-02-25T20:04:34.470Z","updated_at":"2025-02-25T20:04:34.470Z","phase":"Phase 2","brief_title":"Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT06650748 - OBU-BC-II-164","lead_sponsor":"Peking University","biomarkers":" CDK4","pipe":"","alterations":" ","tags":["CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • AiRuiKang (dalpiciclib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/15/2024","start_date":" 11/15/2024","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2024-10-26"},{"id":"41b730ba-cb49-45dd-837c-967e8c4c2b8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03090165","created_at":"2021-01-18T15:13:36.654Z","updated_at":"2025-02-25T15:53:41.650Z","phase":"Phase 1/2","brief_title":"Ribociclib and Bicalutamide in AR+ TNBC","source_id_and_acronym":"NCT03090165","lead_sponsor":"Kari Wisinski","biomarkers":" HER-2 • ER • AR","pipe":" | ","alterations":" HER-2 negative • AR positive • HER-2 negative + ER positive","tags":["HER-2 • ER • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • bicalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 05/07/2018","start_date":" 05/07/2018","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-10-11"},{"id":"61d86a30-55c7-41a4-bec4-37a547f93c03","acronym":"OP-1250-003","url":"https://clinicaltrials.gov/study/NCT05508906","created_at":"2022-08-19T17:10:19.756Z","updated_at":"2025-02-25T15:54:36.272Z","phase":"Phase 1","brief_title":"Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus","source_id_and_acronym":"NCT05508906 - OP-1250-003","lead_sponsor":"Olema Pharmaceuticals, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Piqray (alpelisib) • Kisqali (ribociclib) • palazestrant (OP-1250)"],"overall_status":"Recruiting","enrollment":" Enrollment 155","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 05/20/2026","primary_completion_date":" 05/20/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-10-03"},{"id":"705ca92b-fc36-4251-9d03-9ae5802e7b23","acronym":"ROSIE","url":"https://clinicaltrials.gov/study/NCT06624020","created_at":"2025-02-25T20:04:33.245Z","updated_at":"2025-02-25T20:04:33.245Z","phase":"","brief_title":"A Study to Learn About How Medicines Called CDK4/6 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in Australia","source_id_and_acronym":"NCT06624020 - ROSIE","lead_sponsor":"Pfizer","biomarkers":" CDK4","pipe":"","alterations":" ","tags":["CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Completed","enrollment":" Enrollment 1128","initiation":"Initiation: 05/20/2024","start_date":" 05/20/2024","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-10-02"},{"id":"4fbff4f7-3c54-4d7e-abb5-f4270525f631","acronym":"PONTIAC","url":"https://clinicaltrials.gov/study/NCT06486883","created_at":"2025-02-25T20:04:28.924Z","updated_at":"2025-02-25T20:04:28.924Z","phase":"Phase 2","brief_title":"Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype","source_id_and_acronym":"NCT06486883 - PONTIAC","lead_sponsor":"MedSIR","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • fulvestrant"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-07-04"},{"id":"013fa224-7354-475f-bf22-774d9ee304d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03675893","created_at":"2021-01-18T18:01:44.633Z","updated_at":"2024-07-02T16:34:27.103Z","phase":"Phase 2","brief_title":"RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer","source_id_and_acronym":"NCT03675893","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • letrozole • zotatifin (eFT226) • metformin • samotolisib (LY3023414)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 12/24/2018","start_date":" 12/24/2018","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2024-06-11"},{"id":"257efb56-d6a9-4885-8a27-1e1f2000a80a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04469764","created_at":"2021-01-18T21:28:46.959Z","updated_at":"2024-07-02T16:34:37.400Z","phase":"Phase 2","brief_title":"Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer","source_id_and_acronym":"NCT04469764","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" CDK4","pipe":"","alterations":" ","tags":["CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • letrozole • anastrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 10/16/2020","start_date":" 10/16/2020","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-06-07"},{"id":"bd00d9f1-751b-4305-916d-5b6a04c27152","acronym":"","url":"https://clinicaltrials.gov/study/NCT05524584","created_at":"2022-09-01T12:58:56.062Z","updated_at":"2024-07-02T16:34:37.392Z","phase":"Phase 2","brief_title":"Anastrazole, Fulvestrant \u0026 Abemaciclib for HR+HER2- Metastatic Breast Cancer","source_id_and_acronym":"NCT05524584","lead_sponsor":"University of California, Irvine","biomarkers":" PGR","pipe":"","alterations":" ","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant • anastrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-06-07"},{"id":"cb5da6dd-a9b6-436a-acd6-01685f4f5bc2","acronym":"ETHAN","url":"https://clinicaltrials.gov/study/NCT05501704","created_at":"2022-08-15T12:10:47.553Z","updated_at":"2024-07-02T16:34:37.326Z","phase":"Phase 2","brief_title":"ETHAN - ET for Male BC","source_id_and_acronym":"NCT05501704 - ETHAN","lead_sponsor":"Jose Pablo Leone","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/11/2023","start_date":" 10/11/2023","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2036","study_completion_date":" 04/01/2036","last_update_posted":"2024-06-07"},{"id":"d47b55ed-e6e1-495f-81fa-daa9d190b1d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05361655","created_at":"2022-05-05T16:54:00.592Z","updated_at":"2024-07-02T16:34:37.419Z","phase":"","brief_title":"Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor","source_id_and_acronym":"NCT05361655","lead_sponsor":"Pfizer","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Completed","enrollment":" Enrollment 2888","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 09/01/2021","primary_completion_date":" 09/01/2021","study_txt":" Completion: 09/01/2021","study_completion_date":" 09/01/2021","last_update_posted":"2024-06-07"}]